Alpine Immune Sciences, Inc. (ALPN) NASDAQ

Currency In USD

Alpine Immune Sciences, Inc.

Address

188 East Blaine Street

Seattle, WA 98102

United States of America (the)

Phone

206 788 4545

Website

https://www.alpineimmunesciences.com

Sector

Healthcare

Industry

Biotechnology

Employees

142

First IPO Date

June 17, 2015

Key Executives

Name	Title	Pay	Year Born
Mitchell H. Gold	Executive Chairman & Chief Executive Officer	1.02M	1968
Paul Rickey	Senior Vice President, Chief Financial Officer, Treasurer & Secretary	691,100	1979
Stanford Peng	President and Head of Research & Development	940,100	1971
Wolfgang Dummer	Chief Medical Officer	0	1966
Andrew Seth Sandler	Chief Medical Officer	0	1965
Remy Durand	Chief Business Officer	0	1986
Ulrich Martin Fuhs	Vice President of Finance & Chief Accounting Officer	0	1968
Christina Yi	Chief Technology Officer	0	1976
Michelle Greenblatt	Director of Investor Relations & Corporate Communications	0	N/A
Temre Johnson	Head of IR & Corporate Communications	0	N/A

Description

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.